GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Dr Reddys Laboratories Ltd
Dr Reddy's Pydibhimavaram plant gets 2 USFDA observations
REGULATORY ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 08 Oct 2026, 03:55 PM IST  ·  BSE ID: b8f62238-6a0f-4adb-a116-4662a017f918
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr. Reddy's manufacturing plant in Andhra Pradesh received a standard inspection report with two points for improvement from US health regulators.
🤖 AI Summary
  • Dr. Reddy's Pydibhimavaram facility received a Form 483 with two observations post-USFDA inspection.
  • The United States Food and Drug Administration (USFDA) inspected the FTO-11 manufacturing facility.
  • Inspection conducted from October 5, 2026, to October 7, 2026, at the Pydibhimavaram plant.
  • The company will address the observations within the stipulated timeline.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Observations received
2
Inspection dates
October 5, 2026, to October 7, 2026
🏢 How This Affects the Company
⚙️
Operational Impact
The company must address the two observations issued by the USFDA at its Pydibhimavaram facility.
⚠️
Risk Impact
Receiving a Form 483 indicates potential compliance issues that may require corrective actions.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders.
👤
Who Is Affected
All shareholders are affected by routine regulatory compliance updates for manufacturing facilities.
🔍
Management Signal
Management is transparently disclosing regulatory inspection outcomes and committing to remediation.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Company's response to USFDA observations.
Follow-up communication from USFDA.
Impact on future product approvals from FTO-11 facility.
MEDIUM RISK USFDA observations on a manufacturing facility require corrective actions which can impact operations.
💡 Investor Takeaway
Dr. Reddy's Pydibhimavaram FTO-11 facility received two USFDA observations post-inspection conducted Oct 5-7, 2026, which the company will address.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Dr. Reddy's Pydibhimavaram facility received two observations from USFDA following inspection.
  • Company must address observations within stipulated timeline, implying potential operational adjustments.
📅 Company Track Record
Dr. Reddy's Srikakulam plant received 3 USFDA observations in July 2026; a Hyderabad biologics plant flagged seven observations in June 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the outcome of the USFDA inspection at Dr. Reddy's FTO-11 facility?
The USFDA inspection at the FTO-11 facility in Pydibhimavaram resulted in the issuance of a Form 483 with two observations.
When was the USFDA inspection conducted at Dr. Reddy's Pydibhimavaram plant?
The Pre-Approval Inspection (PAI) was conducted by the USFDA at the FTO-11 facility from October 5, 2026, to October 7, 2026.
What will Dr. Reddy's Laboratories do regarding the USFDA observations?
Dr. Reddy's Laboratories stated that it will address the two observations received from the USFDA within the stipulated timeline.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.